NCM
GLMD icon

Nantahala Capital Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Nantahala Capital Management’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,439
Closed -$412K – 126
2022
Q1 		$412K Sell
1,439
-216
-13% -$61.2K 0.02% 109
2021
Q4 		$542K Sell
1,655
-427
-21% -$193K 0.02% 122
2021
Q3 		$1.04M Sell
2,082
-3,166
-60% -$1.66M 0.03% 117
2021
Q2 		$2.87M Sell
5,248
-1,494
-22% -$812K 0.08% 104
2021
Q1 		$4.16M Sell
6,742
-3,963
-37% -$2.74M 0.12% 85
2020
Q4 		$5.99M Sell
10,705
-810
-7% -$506K 0.19% 87
2020
Q3 		$7.32M Hold
11,515
– – 0.22% 74
2020
Q2 		$9.91M Buy
11,515
+4,272
+59% +$3.6M 0.3% 63
2020
Q1 		$4.51M Buy
7,243
+2,359
+48% +$2.24M 0.17% 74
2019
Q4 		$5.08M Hold
4,884
– – 0.16% 70
2019
Q3 		$4.2M Hold
4,884
– – 0.16% 75
2019
Q2 		$6.56M Buy
4,884
+469
+11% +$605K 0.2% 66
2019
Q1 		$6.49M Sell
4,415
-221
-5% -$321K 0.2% 66
2018
Q4 		$5.7M Sell
4,636
-23
-0.5% -$40.2K 0.18% 72
2018
Q3 		$11.4M Buy
4,659
+542
+13% +$1.27M 0.31% 49
2018
Q2 		$8.82M Buy
4,117
+2,402
+140% +$3.48M 0.36% 55
2018
Q1 		$1.72M Sell
1,715
-507
-23% -$739K 0.08% 77
2017
Q4 		$3.66M Buy
+2,222
New +$3.28M 0.16% 61

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nantahala Capital Management's GLMD Position: Q2 2022 in Review

Nantahala Capital Management sold out of Galmed Pharmaceuticals (GLMD) in Q2 2022, closing a stake of 1,439 shares — an estimated $412K sold.

Nantahala Capital Management first reported a position in GLMD in Q4 2017 and held it in 18 quarters. The position peaked at $11.4M in Q3 2018. 22 funds tracked by Wall St. Rank hold GLMD as of Q2 2022.

  • Nantahala Capital Management reported no remaining Galmed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Nantahala Capital Management sold 1,439 Galmed Pharmaceuticals shares in Q2 2022, an estimated $412K.
  • Nantahala Capital Management first reported a position in Galmed Pharmaceuticals in Q4 2017 and held it in 18 quarters.
  • Nantahala Capital Management's Galmed Pharmaceuticals position peaked at $11.4M in Q3 2018.
  • 22 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2022.

Based on Nantahala Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.